Oncternal Therapeutics Announces Closing of $86.2 Million Bought Deal and Full Exercise of Option to Purchase Additional Shares
December 14, 2020 16:01 ET
|
Oncternal Therapeutics
SAN DIEGO, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Increases Previously Announced Bought Deal to $75.0 Million
December 09, 2020 23:50 ET
|
Oncternal Therapeutics
SAN DIEGO, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Announces $40.0 Million Bought Deal Offering
December 09, 2020 18:08 ET
|
Oncternal Therapeutics
SAN DIEGO, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Announces Presentation of Interim Phase 1/2 Data Update for Cirmtuzumab in Combination with Ibrutinib at ASH 2020 Virtual Annual Meeting
December 07, 2020 08:00 ET
|
Oncternal Therapeutics
Best objective response rate of 87% reported for 15 patients with relapsed/refractory mantle cell lymphoma, with a median follow-up of 12.1 months. Median progression-free survival (PFS) was not...
Oncternal Therapeutics Increases Previously Announced Bought Deal to $22.5 Million
November 17, 2020 23:00 ET
|
Oncternal Therapeutics
SAN DIEGO, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Announces $20.0 Million Bought Deal Offering
November 17, 2020 17:28 ET
|
Oncternal Therapeutics
SAN DIEGO, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Announces Presentation of Interim Phase 1 Clinical Trial Data for TK216 in Patients with Relapsed/Refractory Ewing Sarcoma at CTOS 2020 Virtual Annual Meeting
November 11, 2020 08:00 ET
|
Oncternal Therapeutics
Interim Phase 1 data in patients with relapsed/refractory Ewing sarcoma treated at the recommended Phase 2 dose of TK216 demonstrated two durable complete responses, with no relapses after complete...
Oncternal Therapeutics to Present at Stifel Virtual Healthcare Conference
November 09, 2020 16:01 ET
|
Oncternal Therapeutics
SAN DIEGO, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics (Nasdaq: ONCT), today announced that James Breitmeyer, M.D., Ph.D., President and Chief Executive Officer, will present a company...
Oncternal Announces Third Quarter 2020 Financial Results and Provides Business Update
November 04, 2020 17:15 ET
|
Oncternal Therapeutics
Rare Pediatric Disease Designation received from FDA for TK216 for treatment of Ewing sarcomaInterim Phase 1 data for TK216 in 15 evaluable patients with relapsed/refractory Ewing sarcoma demonstrated...
Oncternal Reports Second Quarter 2019 Financial Results and Provides Business Update
August 08, 2019 16:01 ET
|
Oncternal Therapeutics
SAN DIEGO, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Interim objective response rate of 100% in evaluable patients with CLL receiving the recommended dosing regimen of cirmtuzumab + ibrutinib supports...